IPSEN SA SP.ADR 1/4/ EO 1 (F:I7G0) — Market Cap & Net Worth
Market Cap & Net Worth: IPSEN SA SP.ADR 1/4/ EO 1 (I7G0)
IPSEN SA SP.ADR 1/4/ EO 1 (F:I7G0) has a market capitalization of $12.92 Billion (€11.05 Billion) as of May 2, 2026. Listed on the F stock exchange, this Germany-based company holds position #1820 globally and #387 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying IPSEN SA SP.ADR 1/4/ EO 1's stock price €40.80 by its total outstanding shares 329610016 (329.61 Million).
IPSEN SA SP.ADR 1/4/ EO 1 Market Cap History: 2022 to 2026
IPSEN SA SP.ADR 1/4/ EO 1's market capitalization history from 2022 to 2026. Data shows growth from $9.03 Billion to $15.41 Billion (12.25% CAGR).
IPSEN SA SP.ADR 1/4/ EO 1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how IPSEN SA SP.ADR 1/4/ EO 1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of I7G0 by Market Capitalization
Companies near IPSEN SA SP.ADR 1/4/ EO 1 in the global market cap rankings as of May 2, 2026.
Key companies related to IPSEN SA SP.ADR 1/4/ EO 1 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
IPSEN SA SP.ADR 1/4/ EO 1 Historical Marketcap From 2022 to 2026
Between 2022 and today, IPSEN SA SP.ADR 1/4/ EO 1's market cap moved from $9.03 Billion to $ 15.41 Billion, with a yearly change of 12.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €15.41 Billion | +35.14% |
| 2025 | €11.41 Billion | +9.63% |
| 2024 | €10.40 Billion | +5.87% |
| 2023 | €9.83 Billion | +8.84% |
| 2022 | €9.03 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of IPSEN SA SP.ADR 1/4/ EO 1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.92 Billion USD |
| MoneyControl | $12.92 Billion USD |
| MarketWatch | $12.92 Billion USD |
| marketcap.company | $12.92 Billion USD |
| Reuters | $12.92 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About IPSEN SA SP.ADR 1/4/ EO 1
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more